Bioelectronic medicine company electroCore’s (NASDAQ: ECOR) shares are gaining on Monday after the company announced it has entered into an agreement with Medistar2 that will see them serve as the gammaCore Sapphire distributor in Australia.
The gammaCore Sapphire is a non-invasive vagus nerve stimulator that will supply therapy to patients suffering from primary headache disorders.
The deal follows regulatory approval from the Australian Therapeutic Goods Administration to promote and sell the gammaCore Sapphire family of products.
Interested in investing after today’s move?
XTB gives investors access to thousands of UK and international stocks,
including fractional shares from just £1.
Explore stocks with XTB →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Want to invest in the stocks making the news?
Go from following the market to investing in it, with access to thousands
of stocks across major UK and international markets.
See available stocks →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Own the stocks you’re reading about
Invest in real shares across the UK, US and other major global markets
through XTB, all from one investment account.
Explore XTB shares →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
You don’t need to buy a whole share
Fractional shares let you invest from just £1, giving you more control
over how much you put into individual companies.
Explore fractional shares →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Want to see how XTB works first?
Explore the platform with an XTB demo account before deciding whether
you want to invest with real money.
Try the XTB demo →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
The agreement’s initial term is three years and includes minimum purchase commitments, although they were not disclosed.
electroCore said Medistar will launch gammaCore Sapphire at the 2021 ANZHS Headache Annual Scientific Meeting, which will be held on March 13-14.
“Medistar has demonstrable expertise in medical device distribution in Australia and we are incredibly excited to have its team working on behalf of electroCore,” said Iain Strickland, electroCore’s Vice President of European Operations.
Shares of electroCore are 37.33% higher heading into the open on Wall Street, currently priced at $2.98.
